An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS
BENGALURU, Oct 8 (Reuters) – Aurobindo Pharma Ltd wants to discontinue the late-stage trial of Merck & Co’s(MRK.N) experimental antiviral drug molnupiravir in moderate COVID-19 patients, the Indian drug regulator’s expert committee said on Friday.
Reporting by Shivani Singh in Bengaluru; Editing by Rashmi Aich
Our Standards: The Thomson Reuters Trust Principles.